

Kentucky Department for Medicaid Services

Drug Review Options

The following chart lists the agenda items scheduled and the options submitted for review at the March 15, 2007, meeting of the Pharmacy and Therapeutics Advisory Committee.

Item	Options for Consideration
Alcohol Dependence Agents	<ol style="list-style-type: none"> 1. Based on the package inserts and clinical information available (drug interactions, adverse reactions and Black Box Warnings), agents for the treatment of alcohol dependence are equivalent in efficacy but <i>may</i> not be equivalent in safety. 2. DMS to select agent(s) based upon economic evaluation and the P & T Advisory Committee's review of product safety. 3. Agents not selected as preferred based upon economic evaluation and/or safety will require PA. 4. For any new chemical entity, product, or dosage form for the treatment of alcohol dependence or maintenance of alcohol abstinence, require a PA until reviewed by the P & T Advisory Committee.
Anti-emetics: Cannabinoids	<ol style="list-style-type: none"> 1. Prior Authorization on cannabinoids based on indication(s) and/or failure to respond adequately to conventional anti-emetics. 2. DMS to select agent(s) based upon economic evaluation and the P & T Advisory Committee's review of abuse potential. 3. Place quantity limits on cannabinoids. 4. For any new chemical entity, product or dosage form for the cannabinoids, require PA until reviewed by the P & T Advisory Committee
Antibiotics: Doxycycline – Oracea Single Agent Review	<ol style="list-style-type: none"> 1. DMS to select agent based upon economic evaluation. 2. Place an age edit to require PA for patients less than 19 years old. 3. Agents not selected as preferred will require PA.
Antibiotics: Minocycline – Solodyn Single Agent Review	<ol style="list-style-type: none"> 1. DMS to select agent based upon economic evaluation 2. Place an age edit to require PA for patients less than 12 years old. 3. Place a 12 week duration edit. After 12 weeks, PA will be required. 4. Agents not selected as preferred will require PA.
Topical Antifungals: Vusion Single Agent Review	<ol style="list-style-type: none"> 1. Maintain the most cost-effective topical antifungal treatment(s) as first line. 2. DMS to select agent based on economic evaluation. 3. Agents not selected as preferred will require PA.

The following terms will be utilized within the therapeutic monograph to classify medications during Drug Class Reviews. By using these terms, the reviewer will be able to easily identify any clinical differences between the medications within the class being reviewed.

Superior - Following evidence-based review, it is determined that the drug provides a therapeutic advantage, in terms of safety and/or efficacy, over other available products within the same treatment modality.

Equivalent - Following evidence-based review, it is determined that the drug is therapeutically equivalent in both safety and efficacy to other available products within the same treatment modality.

Not Essential - Following evidence-based review, it is determined that the drug has no therapeutic advantage, due to either reduced safety or efficacy, over other available products within the same treatment modality.